Literature DB >> 2693352

Effects of gastrointestinal peptides on gastrointestinal cancer growth.

C M Townsend1, P Singh, J C Thompson.   

Abstract

The trophic effect of gut hormones may have important clinical applications for treatment of gut and pancreatic cancers. We now have developed methods by which we can quantitate gut hormone receptors in normal and neoplastic gut mucosa and pancreas. Analysis of gut and pancreatic tumors for gut hormone receptors may thus allow us to select patients with these cancers who would respond to treatment with hormones, antihormones, or hormone ablation in a manner similar to current strategies that are employed successfully for treatment of patients with breast cancer.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2693352

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  8 in total

Review 1.  On the role of cholecystokinin in pancreatic cancer.

Authors:  M K Herrington; T E Adrian
Journal:  Int J Pancreatol       Date:  1995-04

2.  Investigational Strategies for Detection and Intervention in Early-Stage Pancreatic Cancer. April 24-27, Annapolis, Maryland. Abstracts.

Authors: 
Journal:  Int J Pancreatol       Date:  1994 Oct-Dec

Review 3.  Hormonal therapy of pancreatic carcinoma. Rationale and perspectives.

Authors:  D Perilli; C Mansi; V Savarino; G Celle
Journal:  Int J Pancreatol       Date:  1993-06

Review 4.  Progress toward hormonal therapy of gastrointestinal cancer.

Authors:  R J Bold; J Ishizuka; C M Townsend
Journal:  Ann Surg       Date:  1996-01       Impact factor: 12.969

Review 5.  Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases.

Authors:  Marc J Berna; Robert T Jensen
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295

6.  Prolonged hypergastrinemia does not increase the frequency of colonic neoplasia in patients with Zollinger-Ellison syndrome.

Authors:  M Orbuch; D J Venzon; I A Lubensky; H C Weber; F Gibril; R T Jensen
Journal:  Dig Dis Sci       Date:  1996-03       Impact factor: 3.199

7.  Inhibitory effect of a cholecystokinin antagonist on pancreatic carcinogenesis after pancreatobiliary diversion.

Authors:  P Watanapa; B Flaks; H Oztas; P H Deprez; J Calam; R C Williamson
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

8.  A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy.

Authors:  S Cascinu; E Del Ferro; G Catalano
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.